Bibliography
- Schweizer PA, Becker R, Katus HA, et al. Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation. Drug Des Devel Ther 2011;5:27-39
- European medicines agency. Summary of product characteristics MULTAQ. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001043/WC500044534.pdf [Last accessed at February 2015]
- Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365(24):2268-76
- Food and Drug Administration. FDA drug safety communication: review update of Multaq (Dronedarone) and increased risk of death and serious cardiovascular adverse events. 2011. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm283933.htm#data [Last accessed June 2014]
- European Medicine Agency. European medicines agency recommends restricting use of multaq. benefit-risk balance of anti-arrhythmic medicine remains positive in a limited population of patients with paroxysmal or persistent atrial fibrillation. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/09/news_detail_001344.jsp&mid=WC0b01ac058004d5c1 [Last accessed June 2014]
- Food and Drug Administration. Multaq full prescribing information. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo [Last accessed February 2015]
- Wu J, Thammakhoune J, Dai W, et al. Assessment of dronedarone utilization using US claims databases. Clin Ther 2014;36(2):264-72
- Waikar SS, Liu KD, Chertow GM. Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol 2008;3(3):844-61
- Lapi F, Azoulay L, Yin H, et al. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ 2013;346:e8525
- Pedrós C, Quintana B, Rebolledo M, et al. Prevalence, risk factors and main features of adverse drug reactions leading to hospital admission. Eur J Clin Pharmacol 2014;70(3):361-7
- Tschuppert Y, Buclin T, Rothuizen L, et al. Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol 2007;64:785-91
- Pearson RK, Hauben M, Goldsmith DI, et al. Influence of the MedDRA hierarchy on pharmacovigilance data mining results. Int J Med Inform 2009;78(12):e97-103
- van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002;11(1):3-10
- Biagi C, Venegoni M, Melis M, et al. Dronedarone-associated acute renal failure: evidence coming from the Italian spontaneous ADR reporting database. Br J Clin Pharmacol 2013;75:1351-5
- Coons JC, Plauger KM, Seybert AL, et al. Worsening heart failure in the setting of dronedarone initiation. Ann Pharmacother 2010;44:1496-500
- Young C, Maruthappu M, Wayne RP, et al. Reversible acute kidney injury requiring haemodialysis five days after starting dronedarone in a stable 71-year-old man at risk of cardiovascular polypharmacy. J R Coll Physicians Edinb 2013;43(2):122-5
- Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-87
- Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78
- Savage R. Dronedarone – acute renal failure and decreased creatinine clearance. WHO Signal 2010, September: 9-11. Restricted document
- The institute for safe medication practices. QuarterWatch: 2010 Quarter 1 monitoring medwatch reports November 4, 2010 signals for acetaminophen, dronedarone and botulinum toxin products. Available from: http://www.ismp.org/QuarterWatch/2010Q1.pdf [Last accessed February 2015]